Abstract

Restless legs syndrome (RLS) and Parkinson's disease (PD) are both common neurological disorders. There has been much debate over whether an etiological link between these two diseases exists and whether they share a common pathophysiology. Evidence pointing towards a link includes response to dopaminergic agents in PD and RLS, suggestive of underlying dopamine dysfunction in both conditions. The extrastriatal dopaminergic system, in particular altered spinal dopaminergic modulation, may be variably involved in PD patients with RLS symptoms. In addition, there is now evidence that the nigrostriatal system, primarily involved in PD, is also affected in RLS. Furthermore, an association of RLS with the parkin mutation has been suggested. The prevalence of RLS has also been reported to be increased in other disorders of dopamine regulation. However, clinical association studies and functional imaging have produced mixed findings. Conflicting accounts of emergence of RLS and improvement in RLS symptoms after deep brain stimulation (DBS) also contribute to the uncertainty surrounding the issue. Among the strongest arguments against a common pathophysiology is the role of iron in RLS and PD. While elevated iron levels in the substantia nigra contribute to oxidative stress in PD, RLS is a disorder of relative iron deficiency, with symptoms responding to replacement therapy. Recent ultrasonography studies have suggested that, despite overlapping clinical features, the mechanisms underlying idiopathic RLS and RLS associated with PD may differ. In this review, we provide a concise summary of the clinical, imaging and genetic evidence exploring the link between RLS and PD.

Highlights

  • The common features of dopaminergic dysfunction and response to dopaminergic agents in Restless legs syndrome (RLS) and Parkinson’s disease (PD), together with comorbidity in some patients has fuelled the concept that these two diseases may share the same pathophysiology [1]

  • Certain similarities and differences exist between RLS and PD

  • Dopaminergic disturbance appears to underpin both diseases suggesting that there may be some overlap in pathophysiology

Read more

Summary

Introduction

The common features of dopaminergic dysfunction and response to dopaminergic agents in RLS and PD, together with comorbidity in some patients has fuelled the concept that these two diseases may share the same pathophysiology [1]. 8.2% of patients had RLS-like symptoms (satisfying the first 3 IRLSSG criteria) compared to 0.9% of controls. At autopsy of 8 patients with primary RLS, there was a significant decrease in dopamine 2 (D2) receptors in the putamen compared to a neurologically normal control group. The findings in RLS have been inconclusive, with some studies showing mild reduction in postsynaptic dopaminergic status [53,54], and another, normal D2 receptor binding compared to controls [55]. Two [18 F]-dopa PET studies demonstrated a slight decrease in striatal [18 F]-dopa uptake in RLS patients compared to healthy controls [54,56], suggesting presynaptic dopaminergic dysfunction in the striatum. A neuropathological study demonstrated increased transferrin with decreased transferrin receptor expression in neuromelanin cells from the substantia nigra of four RLS brains compared to four control brains. The reports purporting to DBS and RLS are conflicting, and more studies need to be done to clarify the effect, with attention to adjustments in dopaminergic medications

Conclusions
Tan EK
11. Ekbom KA
Findings
41. Lyons MK
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call